Late diagnosis of severe cancer and inability to offer focused treatment condemns many people to needless pain and premature death. For drugs companies, diversifying the offer of early diagnosis and treatment of patients with cancer is a challenge.

To support pharmaceutical and nanomedicine R&D, Superbranche is an independent, competitive and innovative partner. Superbranche is a manufacturer of nanotechnological materials for everything from diagnosis to therapy which allows for the monitoring of cell therapies.

At the heart of its innovation: the conception of dendronized magnetic nanoparticles to establish an early diagnosis and a targeted therapy in order to reduce side effects and lead to personalized medicine.

Superbranche’s expertise is strategic for nanomedicine.

Winner of the 2019 i-Lab Grand Jury Prize for its remarkable project and part of the “100 startups to invest in in 2021” according to Challenges Magazine.

It’s a startup that will master the entire value chain, from production to the marketing of clinical nanomedicines. It is a collective interest to produce the drugs and medical devices of the future in France. Superbranche will be one of the leaders.